German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany. 15. Januar 2018 Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017. Oncol Res Treat 40 (suppl 3)(P524), 139–140. Application study of the EQ-5D-5L in Oncology: Linking self-reported quality of life of patients with metastatic colorectal cancer to clinical data from a German tumor registry. Borchert, K., Jacob, C., Wetzel, N., Jänicke, M., Eggers, E., Sauer, A., Marschner, N., Meise, D., Altevers, J., Mittendorf, T., Braun, S., Greiner, W., 2017. Weiterlesen Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study. Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß,… Weiterlesen